IP Library Granted Patent US 11,034,936
Granted Patent B2
US 11,034,936 · App. 16/359,677 · Granted Jun 15, 2021

Bacteriophage and methods of making and using

Inventors: Dongmei Xu (Glen Allen, VA); Elisabeth Miller (Chesterfield, VA); James Arthur Strickland (Richmond, VA); Ujwala Warek (Chester, VA); Steven Hagens (Bennekom, NL)
Assignee: Altria Client Services LLC
C12N7/00A24B15/20C07K14/005C12N9/2462C12Y302/01017C12N2795/00021C12N2795/00022C12N2795/00031C12N2795/12031
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,034,936
App. No.
16/359,677
Granted
Jun 15, 2021
Kind
B2
Abstract

Bacteriophage are provided, and methods of making and using the bacteriophage also are provided.

Claims (20)

1. A method of reducing the number of viable bacteria in tobacco comprising contacting said tobacco with an effective amount of a composition comprising a bacteriophage comprising a nucleic acid sequence at least 90% identical to SEQ ID NO: 1, wherein the reduced number of viable bacteria is as compared to a control tobacco in the absence of said composition.

2. The method of claim 1 , wherein said tobacco comprises cured tobacco.

3. The method of claim 1 , wherein said tobacco comprises reconstituted leaf tobacco.

4. The method of claim 1 , wherein said nucleic acid sequence comprises a nucleic acid sequence at least 95% identical to SEQ ID NO: 1.

5. The method of claim 1 , wherein said nucleic acid sequence comprises a nucleic acid sequence 100% identical to SEQ ID NO: 1.

6. The method of claim 1 , wherein said nucleic acid sequence encodes a polypeptide comprising an amino acid sequence at least 95% identical to SEQ ID NO: 2.

7. The method of claim 1 , wherein said nucleic acid sequence encodes a polypeptide comprising an amino acid sequence 100% identical to SEQ ID NO: 2.

8. The method of claim 1 , wherein said bacteria is from a genus selected from the group consisting of Staphylococcus and Geobacillus.

9. The method of claim 1 , wherein said method further comprises the reduction of at least one tobacco-specific nitrosamine by at leas 10% as compared to said control tobacco plant in the absence of said composition.

10. A method of reducing the number of viable bacteria in tobacco comprising contacting said tobacco with an effective amount of a composition comprising a bacteriophage comprising a nucleic acid sequence encoding an amino acid sequence comprising at least 90% sequence identity to SEQ NO: 2, wherein the reduced number of viable bacteria is as compared to a control tobacco in the absence of said composition.

11. The method of claim 10 , wherein said tobacco comprises cured tobacco.

12. The method of claim 10 , wherein said tobacco comprises reconstituted leaf tobacco.

13. The method of claim 10 , wherein said amino acid sequence comprises at least 95% sequence identity to SEQ ID NO: 2.

14. The method of claim 10 , wherein said amino acid sequence comprises 100% sequence identity to SEQ ID NO: 2.

15. The method of claim 10 , wherein said nucleic acid sequence comprises at least 95% sequence identity to SEQ ID NO: 1.

16. The method of claim 10 , wherein said nucleic acid sequence comprises 100% identity to SEQ ID NO: 1.

17. The method of claim 10 , wherein said bacteria is from a genus selected from the group consisting of Staphylococcus and Geobacillus.

18. The method of claim 10 , wherein said method further comprises the reduction of at least one tobacco-specific nitrosamine by at least 10% as compared to said control tobacco plant in the absence of said composition.

19. A method of reducing at least one tobacco-specific nitrosamine (TSNA) in tobacco comprising contacting said tobacco with an effective amount of a composition comprising a bacteriophage comprising a nucleic acid sequence encoding an amino acid sequence comprising at least 90% sequence identity to SEQ ID NO: 2, wherein the reducing at least one TSNA is as compared to a control tobacco in the absence of said composition.

20. The method of claim 19 , wherein the at least one TSNA is reduced by at least 10%.

Continuity (4)
Continuation 15256228 · Sep 2, 2016
Continuation 14205660 · Mar 12, 2014
Provisional Application 61791976 · Mar 15, 2013
Related Publication 20190203185A1 · Jul 4, 2019